VPC
Vestal Point Capital Portfolio holdings
AUM
$1.9B
1-Year Return
12.28%
This Quarter Return
+0.42%
1 Year Return
-12.28%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$1.9B
AUM Growth
+$499M
(+36%)
Cap. Flow
+$501M
Cap. Flow
% of AUM
26.36%
Top 10 Holdings %
Top 10 Hldgs %
45.18%
Holding
85
New
22
Increased
26
Reduced
12
Closed
13
Top Buys
| 1 |
Jazz Pharmaceuticals
JAZZ
|
+$127M |
| 2 |
Alcon
ALC
|
+$46.3M |
| 3 |
Revolution Medicines
RVMD
|
+$44.1M |
| 4 |
Amicus Therapeutics
FOLD
|
+$43.7M |
| 5 |
Exact Sciences
EXAS
|
+$37.2M |
Top Sells
| 1 |
Insmed
INSM
|
+$82M |
| 2 |
UroGen Pharma
URGN
|
+$23.8M |
| 3 |
Ultragenyx Pharmaceutical
RARE
|
+$18.1M |
| 4 |
Liquidia Corp
LQDA
|
+$18.1M |
| 5 |
Establishment Labs
ESTA
|
+$17.7M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Savara
SVRA
$660M
| $25.1M | 1.32% |
11,015,000
+15,000
| +0.1% | +$34.2K |
|
27
Cooper Companies
COO
$13.6B
| $24.9M | 1.31% |
+350,000
| New | +$24.9M |
|
28
Structure Therapeutics
GPCR
$1.22B
| $24.9M | 1.31% |
1,200,000
-588,990
| -33% | -$12.2M |
|
29
Cidara Therapeutics
CDTX
$1.6B
| $24.4M | 1.28% |
500,000
-4,542
| -0.9% | -$221K |
|
30
Astria Therapeutics
ATXS
$425M
| $24.2M | 1.28% |
4,522,000
+342,000
| +8% | +$1.83M |
|
31
Abbott
ABT
$230B
| $23.8M | 1.25% |
+175,000
| New | +$23.8M |
|
32
Edwards Lifesciences
EW
$46.9B
| $23.5M | 1.24% |
+300,000
| New | +$23.5M |
|
33
Nurix Therapeutics
NRIX
$703M
| $22.8M | 1.2% |
2,000,000
+874,448
| +78% | +$9.96M |
|
34
Cogent Biosciences
COGT
$1.79B
| $22.1M | 1.16% |
3,080,000
+80,000
| +3% | +$574K |
|
35
Bruker
BRKR
$4.73B
| $20.6M | 1.08% |
500,000
+200,000
| +67% | +$8.24M |
|
36
Ionis Pharmaceuticals
IONS
$10.3B
| $19.8M | 1.04% |
+500,000
| New | +$19.8M |
|
37
Day One Biopharmaceuticals
DAWN
$758M
| $19.5M | 1.03% |
3,000,000
+401,873
| +15% | +$2.61M |
|
38
Medtronic
MDT
$121B
| $17M | 0.89% |
+195,000
| New | +$17M |
|
39
Perrigo
PRGO
$3.07B
| $16.7M | 0.88% |
625,000
+37,351
| +6% | +$998K |
|
40
Zymeworks
ZYME
$1.15B
| $14.4M | 0.76% |
1,150,000
+650,000
| +130% | +$8.16M |
|
41
Black Diamond Therapeutics
BDTX
$185M
| $13.9M | 0.73% |
5,600,000
| – | – |
|
42
Lexeo Therapeutics
LXEO
$280M
| $13M | 0.68% |
3,228,161
+2,091,912
| +184% | +$8.41M |
|
|
NYXH
43
Nyxoah
NYXH
$214M
| $10.5M | 0.55% |
1,402,002
-916,952
| -40% | -$6.86M |
|
44
Thermo Fisher Scientific
TMO
$182B
| $10.1M | 0.53% |
+25,000
| New | +$10.1M |
|
45
Danaher
DHR
$139B
| $9.88M | 0.52% |
50,000
-75,000
| -60% | -$14.8M |
|
|
BBNX
46
Beta Bionics, Inc. Common Stock
BBNX
$1.09B
| $8.01M | 0.42% |
+550,000
| New | +$8.01M |
|
47
Disc Medicine
IRON
$2.1B
| $7.41M | 0.39% |
+140,000
| New | +$7.41M |
|
48
Solid Biosciences
SLDB
$389M
| $7.33M | 0.39% |
1,505,000
-248,558
| -14% | -$1.21M |
|
49
Taysha Gene Therapies
TSHA
$895M
| $6.93M | 0.36% |
+3,000,000
| New | +$6.93M |
|
50
Dyne Therapeutics
DYN
$1.88B
| $6.93M | 0.36% |
727,500
-1,072,500
| -60% | -$10.2M |
|